Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A major focus of current treatment research in schizophrenia is the determinants of long-term outcome, including functional outcome and general medical well being, rather than just specific domains of psychopathology such as positive and negative symptoms, mood symptoms, and cognitive impairment. This focus does not negate the importance of the latter issues but sees them as factors contributing to long-term outcome to variable extents. A long-term treatment focus facilitates a more clinically relevant assessment of benefits versus risks of available treatments. For instance, atypical antipsychotic drugs as a group have clear advantages for several important domains of efficacy that may influence long-term outcome, but are also more expensive over the long term. Use of some agents may also result in deleterious physical health consequences as well as large additional costs over the long term owing to metabolic adverse effects. The present paper focuses on several key issues in schizophrenia which are important determinants of long-term outcome in schizophrenia, or influence choice of antipsychotic drugs, or both, including: (i) duration of untreated psychosis; (ii) impact of relapse on long-term outcome; (iii) limited efficacy for specific domains of psychopathology of current treatments; (iv) mortality owing to suicide; and (v) mortality owing to other causes (e.g. cardiovascular disease).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589 · cited 2×
“Suicide accounts for approximately 10% of deaths among patients with schizophrenia (Harris and Barraclough, 1997; Meltzer, 1999).”
BackgroundInfluentialAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 2×
“It is well established that antipsychotic medications, typical or atypical, can all cause increases in weight and adiposity (Allison et al., 1999); however, the relative risk between agents may differ substantially.”
BackgroundExcess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 4×
“This is, in part, on the basis of the hypothesis that a neurodegenerative process present during the psychotic phase of the illness produces persistent damage to neural function (Olney and Farber, 1995; Wyatt, 1995; Theberge et al., 2004).”
BackgroundInfluentialConsensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · cited 4×
“Moderate risk was associated with quetiapine and rispieridone, whereas the lowest risk was associated with aripiprazole and ziprasidone (American Diabetes Association, 2004).”
BackgroundInfluentialDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 3×
“With the exception of amisulpride, a substituted benzamide, atypical antipsychotic agents share in common more potent blockade of serotonin (5-HT)2A than D2 receptors (Meltzer et al., 2003a).”
BackgroundSelf-citationCauses of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087 · cited 1×
“A 13-year follow-up of 370 patients was carried out to measure the standardized mortality ratio (SMR) and examine reasons for excess mortality (Brown et al., 2000).”
BackgroundThe Lifetime Risk of Suicide in Schizophrenia: A Reexamination
Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.3.247 · Cited by 1,026 · cited 3×
“Most successful attempts appear to occur early in the disease process, especially within the first year and decade after the onset of illness (Nordentoft et al., 2004; Palmer et al. 2005), though it is also known that the risk of suicide in”
BackgroundInfluentialExcess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Natural Course of Schizophrenic Disorders: A 15-Year Followup of a Dutch Incidence Cohort
Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033315 · Cited by 649
Effects of adverse experiences for brain structure and function
McEwen, B. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00964-1 · Cited by 639
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · cited 1×
“In a randomized double-blind study, risperidone and haloperidol were compared in stable patients with schizophrenia (Csernansky et al., 2002).”
BackgroundQTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“One toxicity model suggests that N-methyl-D-aspartic acid receptor hypofunctioning may induce psychosis and produce glutamatergically medicated excitotoxic damage in neurons at the same time (Olney and Farber, 1995; Coyle, 1996).”
BackgroundDelayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408 · cited 2×
“…observation that 2–4 weeks are often required to show an initial response, a notion that has been challenged by a recent meta-analysis, the results of which suggest that onset of some antipsychotic response may occur within the first week of treatment and accumulate over time (Agid et al., 2003).”
ResultCognition in Schizophrenia: Impairments, Determinants, and Functional Importance
Bowie, C. R., & Harvey, P. D. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.05.004 · Cited by 280
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277 · cited 1×
“…risperidone, recently published short-term studies which compared clozapine alone to combined treatment using clozapine and risperidone reported no significant differences in response between groups on measures of symptom severity and cognition (Anil Yagcioglu et al., 2005; Honer et al., 2006).”
ResultUse of General Medical Services by VA Patients With Psychiatric Disorders
Cradock-O'Leary, J., Young, A. S., Yano, E. M., Wang, M., & Lee, M. L. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.7.874 · Cited by 197
Compliance with antipsychotic treatment
Oehl, M., Hummer, M., & Fleischhacker, W. W. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.00016.x · Cited by 151 · cited 1×
“Several studies suggest that > 50% of individuals with schizophrenia are noncompliant with their medications at some point in their illness (Oehl et al., 2000).”
BackgroundThe natural history and pathophysiology of treatment resistant schizophrenia
Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140 · cited 1×
“As most patients with schizophrenia have at least some residual symptoms even under the best of circumstances (Sheitman and Lieberman, 1998; Pantelis and Lambert, 2003), this alone cannot adequately define treatment resistance.”
BackgroundLong-Term Diagnostic Stability and Outcome in Recent First-Episode Cohort Studies of Schizophrenia
Bromet, E. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi030 · Cited by 129 · cited 1×
“Evidence exists that DUP may be an important predictor of longterm outcome in schizophrenia (Altamura et al., 2001; Bottlender et al., 2003; Bromet et al., 2005; Harris et al., 2005; Perkins et al., 2005).”
BackgroundClozapine Eligibility Among State Hospital Patients
Essock, S. M., Hargreaves, W. A., Dohm, F.-A., Goethe, J., Carver, L., & Hipshman, L. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.1.15 · Cited by 107
Mortality in Western Australian psychiatric patients
Lawrence, D., Jablensky, A. V., Holman, C. D. J., & Pinder, T. J. (2000) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270050248 · Cited by 95
Cited by
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257
Duration of untreated illness as a key to early intervention in schizophrenia: a review.
Murru, A., & Carpiniello, B. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.003 · Cited by 135
“Furthermore, prolonged stress resulting from DUP may activate the hypothalamicpituitary-adrenal axis, leading to greater glucocorticoid secretion which, in turn, may contribute to neuronal damage [58].”
BackgroundDell’Osso, B., Glick, I. D., Baldwin, D. S., & Altamura, A. C. (2013) · Psychopathology · doi:10.1159/000338608 · Cited by 118
Self-citationZisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05699gre · Cited by 45
Metadata
- Authors
- Carlo Altamura, A., Bobo, W. V., & Meltzer, H. Y.
- Venue
- International Clinical Psychopharmacology
- Published
- 2007-09
- Volume
- 22
- Issue
- 5
- Pages
- 249-267
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2001797784
- Cited by
- 56
- References
- 24
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.